Livanova

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LivaNova reports solid Q4 earnings, eyes growth amidst industry challenges

LivaNova's Q4 2022 showcased revenue growth and operational resilience amid challenges. With a strong cash position and strategic focus, the company aims for continued growth in 2023. Managing inflation, supply chain issues, and debt levels will be crucial for sustained success.

Livanova reports robust Q1 earnings, eyes growth amid market recovery

Livanova's Q1 2023 showcased strong revenue growth driven by Cardiopulmonary and Neuromodulation segments, with strategic initiatives progressing well.
While facing challenges in ACS revenue and epilepsy monitoring trends, the company remains focused on patient care and innovation.
Opportunities lie in market recovery, international business growth, and continued progress in strategic initiatives for future expansion.
Overall, Livanova's performance reflects resilience, adaptability, and a commitment to driving shareholder value creation.

LivaNova reports strong Q2 revenue growth and strategic initiatives progress

LivaNova's Q2 2023 earnings call highlighted robust revenue growth, improved margins, and strategic initiatives driving positive momentum. While facing legal challenges and patient access issues, the company is investing in core business growth and innovation for future opportunities.

LivaNova reports strong Q3 results, eyes growth amid leadership transition

LivaNova's Q3 2023 performance showcased revenue growth, margin expansion, and increased earnings per share, underpinned by operational efficiency.
While facing challenges in cost management and leadership transition, the company is poised for growth with opportunities in segment performance and margin improvement.
Increased guidance for full-year 2023 reflects confidence in future prospects, with a focus on product launches and clinical study progress.
Anticipated tax rate changes and the need for successful volume scaling present considerations for future financial planning and operational execution.

LivaNova reports strong Q4 growth, eyes revenue expansion in 2024

LivaNova's Q4 2023 performance showed revenue growth, margin impact from cybersecurity incident, and positive guidance for 2024.
The company's strengths lie in segment reorganization, income improvement prospects, and strategic focus on growth areas.
Challenges include cybersecurity disruptions, legal uncertainties, tax rate fluctuations, and unaccounted stock-based compensation impacts.
Opportunities in revenue growth, product expansion, international market penetration, and strategic planning with new leadership are key focus areas.

LivaNova reports robust Q1 earnings, eyes growth through innovation

LivaNova's Q1 performance reflects a solid start to 2024, driven by revenue growth and strong financial metrics. The company's strategic focus on innovation, clinical studies, and disciplined growth strategies positions it well for future success in the healthcare market.

LivaNova reports strong Q2 earnings, eyes growth through strategic focus

LivaNova's Q2 2024 earnings call highlighted robust financial performance, strategic imperatives, and revised guidance. The company aims to capitalize on its strengths in cardiopulmonary and epilepsy businesses while addressing challenges in litigation and expenses. Opportunities for growth are evident through revised guidance and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Brighthouse Financial

Change Healthcare Inc

Capri Holdings Ltd

Green Brick Partners

Jack in the Box

Sonos

David Einhorn stocks did better than the S&P 500 in Q4 2021, gaining 18.6%, 760 basis points higher. Buy these seven holdings.

7 Top David Einhorn Stock Picks to Add to Your March Buy List

LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC announced the first patient implanted in clinical study, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation.”

LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea

McDonald's

LivaNova PLC (LIVN) CEO Damien McDonald on Q4 2021 Results - Earnings Call Transcript

LivaNova (LIVN) delivered earnings and revenue surprises of 14% and 2.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Surpasses Q4 Earnings and Revenue Estimates

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter and full year ended December 31, 2021.

LivaNova Reports Fourth-Quarter and Full-Year 2021 Results

As per our first article, DTD remains incredibly attractive, even with conservative prevalence figures.

LivaNova Continues To Be A Spring-Loaded Opportunity In Neuromodulation

LivaNova (LIVN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can LivaNova (LIVN) Keep the Earnings Surprise Streak Alive?

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wed., Feb. 23, 2022 at 1 p.m. London (8 a.m. ET)

LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results

LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC today announced its participation in the American Epilepsy Society Annual Meeting taking place December 3 – 7 in Chicago, Illinois.

LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting

LONDON--(BUSINESS WIRE)--LivaNova PLC today announced its participation in the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C.

LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference

LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova PLC announced Damien McDonald, CEO, will participate in discussions at the Piper Sandler 33rd Annual Virtual Healthcare Conference on Dec. 1.

LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

The courts in Milan ruled that LivaNova would be liable for $519 million in damages in connection with a former parent company from Sorin with which it merged years ago.

Milan Court Decision Does Not Change LivaNova Bullish Story

LONDON--(BUSINESS WIRE)--LivaNova commented on the decision delivered today by the Court of Appeal of Milan for LivaNova to pay damages as a result of a civil action.

LivaNova Comments on Decision by Court of Appeal of Milan

LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova announced CEO Damien McDonald will present at Stifel 2021 Virtual Healthcare Conference and at Jefferies 2021 London Healthcare Conference.

LivaNova to Present at the 2021 Stifel and Jefferies Healthcare Conferences

LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova today announced it will host a virtual Investor Day on December 7 from 8 a.m.-12 p.m. Central Time (9 a.m.-1 p.m. Eastern Time).

LivaNova Announces 2021 Virtual Investor Day

LivaNova PLC (LIVN) CEO Damien McDonald on Q3 2021 Results - Earnings Call Transcript

LivaNova PLC (NASDAQ: LIVN) posted Q3 sales of $253.2 million, +5.5% Y/Y on a reported basis and 5% on a constant-currency basis, beating the consensus of $245.27 million. Excluding Heart Valves business, divested in June, sales increased by 15.7% on a reported basis and 15.2% on a constant currency.

LivaNova Shares Move Higher On Street-Beating Q3 Earnings

LivaNova (LIVN) delivered earnings and revenue surprises of 51.11% and 3.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Q3 Earnings and Revenues Surpass Estimates

LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2021.

LivaNova Reports Third Quarter 2021 Results

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LivaNova (LIVN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

LivaNova (LIVN) has been struggling lately, but the selling pressure may be coming to an end soon.

LivaNova (LIVN) Sees Hammer Chart Pattern: Time to Buy?

LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova PLC will host a conference call to discuss its third quarter 2021 results on Wednesday, Nov. 3, 2021 at 12 p.m. London/8 a.m. Eastern time.

LivaNova to Host Conference Call for Third Quarter 2021 Results

American Water Works

Cable One

Consolidated Communications Holdings

Fastenal

General Electric

ICU Medical

Las Vegas Sands

Paychex

Vonage Hlds

Expensive stocks with mediocre growth prospects can drop the most when the whole market starts to slide. These 10 stocks could be at high risk.

10 Expensive Stocks to Steer Clear Of

LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova today announced CEO Damien McDonald will present at the Baird 2021 Global Healthcare Conference on Wednesday, September 15 at 9:40 a.m. ET.

LivaNova to Present at the Baird 2021 Global Healthcare Conference

Special situation of a business opportunity suddenly coming back to life with no one noticing. Compelling situation in valuable markets from an insurance pickup perspective, meaning a business option is afoot.

News for Livanova Stock (LIVN)